S&P Futures
3,900.75 -3.00 (-0.08%) Dow Futures
31,415.00 -6.00 (-0.02%) Nasdaq Futures
12,025.25 -15.25 (-0.13%) Russell 2000 Futures
1,770.40 +0.60 (+0.03%) Crude Oil
110.92 +1.35 (+1.23%) Gold
1,827.70 +2.90 (+0.16%)
Decibel Therapeutics, Inc. (DBTX)
Chart Events
Performance Outlook
| Previous Close | 2.4900 |
| Open | 2.4200 |
| Bid | 2.2400 x 900 |
| Ask | 2.9600 x 900 |
| Day's Range | 2.2300 - 2.4700 |
| 52 Week Range | 1.8310 - 9.7500 |
| Volume | |
| Avg. Volume | 72,267 |
| Market Cap | 55.828M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Decibel Therapeutics to Present at the Jefferies Global Healthcare Conference
BOSTON, June 03, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that John Lee, chief development officer, and Lis Leiderman, M.D., MBA, chief financial officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Friday, June 10, 2022 at 9:00 a.m. ET. A live webcast of the fireside chat
- GlobeNewswire
Decibel Therapeutics to Present at the H.C. Wainwright Global Investment Conference
BOSTON, May 17, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Officer of Decibel, will participate in a fireside chat at the H.C. Wainwright Global Investment Conference. The fireside chat will be available for on-demand viewing starting Tuesday, May 24, 2022 at 7:00 a.m. E.T
- GlobeNewswire
Decibel Therapeutics Reports First Quarter 2022 Financial Results and Corporate Update
- Multiple milestones anticipated for 2022 including submission of IND and/or CTA for DB-OTO, top-line results from interim analysis of Phase 1b trial of DB-020 for cisplatin-induced hearing loss and product candidate selection for AAV.103 program – - New preclinical data presented at the 45th Annual Association for Research in Otolaryngology Conference (ARO) supporting DB-OTO and emphasizing platform focus on cell-selective transgene expression – - Preclinical data to be presented at the Americ
